Announced Fri, 24 Jul · 08:50 IST
Sun Pharma notes Organon shareholder approval for acquisition
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.1%1-day move
₹1951.00
prior close
₹1945.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3+0.5+0.5+0.6+1.1—————————
Up moveDown movePending
AI summary
Organon's stockholders have approved Sun Pharma's proposal to acquire Organon and Co. Under the deal, Organon will become a wholly owned subsidiary of Sun Pharma's US arm. This marks an important milestone toward closing the transaction, first announced on April 27, 2026. The acquisition still needs regulatory approvals and other customary closing conditions before completion.
Likely market impact
Positive milestone for Sun Pharma's Organon acquisition. Deal still awaits regulatory approvals. Could expand global product portfolio if completed.